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	 p r e v i e w sThe DNA mismatch repair (MMR) pathway 
plays a critical role in the maintenance 
of genome integrity. The evolutionarily 
conserved MMR pathway functions in 
postreplicative genome surveillance by 
repairing base substitution mutations as 
well as small insertions/deletions (IDLs) 
caused by replication errors. In mam-
malian cells, MMR is initiated by MSH2-
containing heterodimeric complexes of 
MSH2-MSH6 (MutSα) and MSH2-MSH3 
(MutSβ). The MutSα complex recogniz-
es base-base mispairs and single base 
IDLs, while the MutSβ complex detects 
larger IDLs to initiate the repair proc-
ess. The MutSα and MutSβ complexes 
undergo ATP-hydrolysis-dependent con-
formational transitions following binding 
to DNA mispairs or IDLs to recruit a het-
erodimeric complex of MLH1 and PMS2 
(MutLα). This interaction between the 
MutS and the MutL complexes is 
essential for the activation of sub-
sequent MMR steps, i.e., the exci-
sion of the mispairs and IDLs and 
the resynthesis of the DNA strand 
(Buermeyer et al., 1999; Kolodner 
and Marsischky, 1999; Kunkel 
and Erie, 2005; Iyer et al., 2006). 
Hereditary mutations in MSH2 
and MLH1 predispose humans to 
colon and endometrium cancers, 
and mice to intestinal cancer and 
lymphoma. Epigenetic silencing of 
MLH1 has also been detected in 
a wide variety of sporadic human 
cancers. Thus, MMR is an impor-
tant tumor suppression mecha-
nism in mammals.
In multicellular organisms, 
DNA repair is complemented by 
the active elimination of damaged 
cells through apoptosis, necrosis, 
mitotic catastrophe, or the induc-
tion of premature senescence, 
to suppress tumor development. 
These damage-induced tumor 
suppression pathways are coor-
dinately regulated by a signaling 
network consisting of damage 
sensors, adaptors, mediators, 
and protein kinases (Wang and Cho, 
2004). Over the past decade, evidence 
has accumulated to suggest that MMR 
not only repairs DNA but also stimulates 
DNA damage-induced G2 checkpoint and 
apoptosis (Iyer et al., 2006; Fishel, 2001; 
Stojic et al., 2004). While MMR-proficient 
cells respond to cisplatin, 6-thioguanine 
(6-TG), and SN1 DNA methylators such 
as temozolomide and MNNG (N-methyl-
N′-nitro-N-nitrosoguanidine) by undergo-
ing G2 arrest followed by programmed cell 
death, MMR-deficient cells are defective 
in this response, resulting in an increased 
resistance to the genotoxic effects of DNA 
damage-inducing agents. Because cispla-
tin and DNA alkylating agents are used 
in cancer therapy, there is considerable 
interest in understanding how MMR-defi-
cient cancer cells acquire resistance to 
these drugs.
Two opposing models have been pro-
posed to account for the MMR-depend-
ent activation of the G2 checkpoint and 
programmed cell death—the futile cycle 
model and the direct signaling model.
The futile cycle model
The futile cycle model considers the MMR 
pathway to have a single function, i.e., 
DNA repair. The MMR-dependent activa-
tion of G2 checkpoint or programmed cell 
death is due to the creation of DNA strand 
breaks that result from a futile attempt 
of the MMR pathway to repair alkylated 
DNA (Karran, 2001). Exposure to SN1 
alkylating agents such as MNNG creates 
O6-methylguanine (O6-meG), which can 
pair with cytosine (C) or thymidine (T). 
Replication of a template strand contain-
ing O6-methylguanine would lead to the 
formation of O6-meG/C or O6-meG/T. In 
MMR-proficient cells, O6-meG/C or O6-
meG/T are recognized by MutSα, 
which interacts with MutLα to initi-
ate excision of the newly synthe-
sized strand. Because O6-meG 
is in the template strand, which 
is not excised by MMR, abor-
tive repair cycles would ensue 
to cause DNA strand breaks and 
checkpoint activation. In MMR-
deficient cells, O6-meG/C or O6-
meG/T are not processed, and 
therefore these cells survive and 
display increased mutagenesis.
The direct signaling model
The direct signaling model pro-
poses that MMR complexes have 
two distinct functions, one in repair 
and the other in DNA damage sig-
nal transduction (Kat et al., 1993; 
Fishel, 2001). The MutSα com-
plex, by virtue of its recognition of 
O6-meG/C, O6-meG/T or platinat-
ed DNA, can function as a sensor 
to activate the DNA damage-sig-
naling network. Genetic evidence 
for this model was provided with 
the creation of “separation of 
function” mutants in the murine 
Msh2 and Msh6 genes (Lin et al., 
2004; Yang et al., 2004). In these 
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Figure 1. signaling function of MMr proteins
replication errors (rer) or exposure to MnnG at G/c base 
pairs can result in G/T or O6-meG/T mispairs, respectively. in 
MMr-proficient cells (MMr+), Mutsα and Mutlα signal repair 
of G/T mispairs to restore the G/c base pair (left). As demon-
strated by Yoshioka et al. (2006), Mutsα and Mutlα also bind 
specifically to sites of O6-meG/T mispairs in DnA and recruit 
ATr-ATriP. The recruitment of ATr-ATriP only occurs in the 
presence of Mutsα and Mutlα, leading to the phosphoryla-
tion of chk1 and other downstream targets of ATr kinase 
to activate cell cycle checkpoints (middle). MMr-deficient 
cells (MMr−) escape checkpoint signaling and accumulate 
G:c>A:T mutations at O6-meG/T sites during following rounds 
of replication (right).cancer cell 9, June 2006 ©2006 elsevier inc. 417
	 p r e v i e w sstudies, mouse lines were engineered 
to carry missense mutations in Msh2 
and Msh6, located within the ATP bind-
ing site or in close proximity to it. These 
mutations disrupted the ATP processing 
ability of MutSα, which is an essential 
function for DNA repair in both prokaryo-
tes and eukaryotes. Biochemical analy-
sis of cell extracts from these mouse 
lines showed that, although the mutant 
MutSα complexes had normal affinity to 
mismatched base pairs, the defect in ATP 
processing prevented the downstream 
steps of DNA repair. Nevertheless, the 
mutant MutSα conferred a normal apop-
totic response to MNNG, cisplatin, and 
other agents, demonstrating that DNA 
damage signaling by MMR proteins can 
occur independently of normal strand 
excision. These studies show that the 
repair function of MMR is dispensable for 
the MMR-dependent apoptotic response 
to DNA damage.
The report by Yoshioka et al. (2006) 
in a recent issue of Molecular Cell pro-
vides further evidence for the idea that 
MutSα and MutLα participate directly 
in the activation of ATR by O6-meG/T 
mispairs. The authors demonstrate an 
MMR-dependent and S phase-specific 
activation of ATR, as measured by the 
phosphorylation of Chk1 and SMC1 
(structure maintenance of chromosome 
1), in MNNG-treated HeLa cells. This 
response is not observed in MSH2- or 
MLH1-deficient cells, suggesting that 
MMR recognition of O6-meG/T or O6-
meG/C may be involved in ATR acti-
vation. The authors then showed that 
MutSα bound to O6-meG/C in a nonspe-
cific manner, but it bound to O6-meG/T 
with a high affinity comparable to its 
binding to a G/T mispair, although the 
affinity of MutSα for O6-meG/T varied 
depending on the sequence context. 
When nuclear extracts were incubated 
with plasmids bearing O6-meG/T mis-
pairs, ATR and its associated adap-
tor protein, ATRIP, were found to be 
preferentially crosslinked to the site of 
O6-meG/T, but not to the G/T mispairs 
(Figure 1). The MutSα and MutLα com-
plexes are also preferentially crosslinked 
to plasmid sites bearing the O6-meG/T 
mispairs, although these MMR complex-
es also preferentially crosslinked to the 
G/T mispairs (Figure 1). Furthermore, 418 a DNA-protein complex assembled with 
the O6-meG/T mispair-bearing plasmid 
and nuclear extract phosphorylated 
Chk1, whereas the G/T mispair-bearing 
DNA-protein complex did not contain 
detectable Chk1-kinase activity. The 
O6-meG/T-bearing DNA used in these 
studies was not subjected to nucleolytic 
degradation, indicating that ATR-ATRIP 
recruitment occurs independently of 
MMR-mediated excision repair.
This latest evidence in support of 
MMR complexes as damage sensors 
has raised new questions regarding 
DNA damage signal transduction. The 
direct signaling model would predict 
that a regulatory mechanism exists 
to direct the MMR complexes toward 
either DNA excison/resynthesis or the 
ATR-ATRIP pathways (Figure 1). The 
work of Yoshioka et al. suggests that 
regulation would be dependent on the 
DNA ligand, as the G/T mispair does not 
recruit ATR-ATRIP (but it should recruit 
repair enzymes), whereas the O6-meG/
T mispair recruits ATR-ATRIP (it is 
unclear whether it also recruits repair 
enzymes). The ATR-ATRIP complex has 
been shown to bind RPA-coated single-
stranded (ss) DNA (Zou and Elledge, 
2003). ATR has also been shown to 
physically interact with MSH2 (Wang 
and Qin, 2003). The study of Yoshioka 
et al. demonstrates that the recruitment 
of ATR-ATRIP to the O6-meG/T mis-
pair requires MutSα and MutLα; how-
ever, they did not observe a preferential 
crosslinking of RPA to the O6-meG/T site. 
It is conceivable that MutSα and MutLα 
may recruit ATR-ATRIP independently 
of RPA-ssDNA, or alternatively, a lim-
ited RPA-ssDNA region might be cre-
ated at the O6-meG/T mispair to allow 
the binding of ATR-ATRIP. The obser-
vation that ATR-ATRIP is not recruited 
to G/T mispairs despite the binding of 
MutSα and MutLα at these sites indi-
cates that MMR-dependent assembly of 
the damage-signaling complex requires 
additional factors. Identification of those 
factors is within reach with the DNA-pro-
tein complex assembly methods devised 
by Yoshioka et al. Further dissection of 
the MMR-dependent signaling complex 
would hopefully lead to a resolution of 
the two opposing models on the role of 
MMR in DNA damage response.Acknowledgments
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